Cystic fibrosis future or investigational therapies: Difference between revisions
No edit summary |
|||
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
In cystic fibrosis therapies under investigation include prophylactic ursodiol therapy; CF corrector VX-661; inhaled dry powder mannitol and CFTR gene therapy. | |||
== future or investigational therapies == | == future or investigational therapies == | ||
In cystic fibrosis therapies under investigation include:<ref name="urlCystic Fibrosis and Congenital Absence of the Vas Deferens - GeneReviews® - NCBI Bookshelf">{{cite web |url=https://www.ncbi.nlm.nih.gov/books/NBK1250/ |title=Cystic Fibrosis and Congenital Absence of the Vas Deferens - GeneReviews® - NCBI Bookshelf |format= |work= |accessdate=}}</ref> | |||
* Prophylactic ursodiol therapy | |||
* CF corrector VX-661 | |||
* Inhaled dry powder mannitol | |||
* CFTR gene therapy | |||
==References== | ==References== | ||
Revision as of 21:18, 2 March 2018
|
Cystic fibrosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Cystic fibrosis future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Cystic fibrosis future or investigational therapies |
|
Cystic fibrosis future or investigational therapies in the news |
|
Blogs on Cystic fibrosis future or investigational therapies |
|
Risk calculators and risk factors for Cystic fibrosis future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shaghayegh Habibi, M.D.[2]
Overview
In cystic fibrosis therapies under investigation include prophylactic ursodiol therapy; CF corrector VX-661; inhaled dry powder mannitol and CFTR gene therapy.
future or investigational therapies
In cystic fibrosis therapies under investigation include:[1]
- Prophylactic ursodiol therapy
- CF corrector VX-661
- Inhaled dry powder mannitol
- CFTR gene therapy